Research programme: ATP-citrate lyase inhibitors - Nimbus Therapeutics
Alternative Names: ACLY inhibitors - Nimbus Therapeutics; NDI-091143Latest Information Update: 28 May 2023
At a glance
- Originator Columbia University; Nimbus Therapeutics; Schrodinger
- Class Antineoplastics; Chlorinated hydrocarbons; Esters; Fluorobenzenes; Small molecules; Sulfonamides
- Mechanism of Action ATP citrate (pro S) lyase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2023 No recent reports of development identified for research development in Cancer in USA
- 03 Apr 2019 Early research in Cancer in USA (unspecified route)